Catalyst Wire Dossier Catalyst Wire Dossier

PIK-HER2 cells

· Second Military Medical University
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PIK-HER2 cells, covering 2016-01-01 to 2016-01-01. Get the full timeline:

Most recent: Clinical Trial Update: Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis [Phase 1, Phase 2]

See pricing